［1］Motz GT,Coukos G.Deciphering and reversing tumor immune suppression［J］.Immunity,2013,39(1):61-73.
［2］Yao S,Zhu Y,Chen L.Advances in targeting cell surface signalling molecules for immune modulation［J］.Nat Rev Drug Discov,2013,12(2):130-146.
［3］Corthay A.Does the immune system naturally protect against cancer［J］?Front Immunol,2014,5:197.
［4］Walker LS,Sansom DM.Confusing signals:Recent progress in CTLA-4 biology［J］.Trends Immunol,2015,36(2):63-70.
［5］Shrimali RK,Janik JE,Abu-Eid R,et al.Programmed death-1 & its ligands:Promising targets for cancer immunotherapy［J］.Immunotherapy,2015,7(7):777-792.
［6］Karakatsanis S,Bertsias G,Roussou P,et al.Programmed death 1and B and T lymphocyte attenuators and their association with malignant T-lymphoproliferative disorders:Brief review［J］.Hematol Oncol,2014，32(3):113-119.
［7］Gertner-Dardenne J,Fauriat C,Orlanducci F,et al.The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation:A potential way of immune escape for lymphoma cells［J］.Blood,2013，122(6):922 -931.
［8］Pasero C,Olive D.Interfering with coinhibitory molecules:BTLA/HVEM as new targets to enhance antitumor immunity［J］.Immunol Lett,2013，151(1-2):71-75.
［9］M' Hidi H,Thibult ML,Chetaille B,et al.High expression of the inhibitory receptor BTLA in T-follicular help- er cells and in B-cell small lymphocytic lymphoma /chronic lymphocytic leukem-ia［J］.Am J Clin Pathol,2009，13 2(4):589-596.
［10］Shin DS,Ribas A.The evolution of checkpoint blockade as a cancer therapy:What's here,what's next［J］? Curr Opin Immunol,2015，33C:23-35．
［11］Prokhorov A,Gibbs BF,Bardelli M,et al.The immune receptor Tim-3 mediates activation of PI3 kinase /mTO R and HIF-1 pathways in human myeloid leukaemia cells［J］.Int J Biochem Cell Biol，2015，59:11-20．
［12］Nguyen LT,Ohashi PS.Clinical blockade of PD1 and LAG-3 potential mechanisms of action［J］.Nat Rev Immunol,2015,15(1):45-56．
［13］Gandhi MK,Lambley E,Duraiswamy J,et al.Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients［J］.Blood,2006，108(7):2280-2289．
［14］Dong H,Strome SE,Salomao DR,et al.Tumor-associated B7-H1 promotes T-cell apoptosis:A potential mechanism of immune evasion［J］.Nat Med,2002,8(8):793-800．
［15］Blank C,Kuball J,Voelkl S,et al.Blockade of PD-L1(B7-H1) augments human tumor- specific T cell responses in vitro［J］.Int J Cancer,2006,119(2):317-327.
［16］Hir Ano F,Kaneko K,Tamura H,et al.Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity［J］.Cancer Res,2005,65(3):1089-1096．
［17］Hobo W,Norde WJ,Schaap N,et al.B and T lymphocyte attenuator mediates inhibition of tumor -reactive CD8 +T cells in patients after allogeneic stem cell transplantation［J］．J Immunol，2012,189(1):39-49．
［18］Han L,Wang W,Fang Y,et al.Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical model in vivo［J］.J Immunol,2009,183:7842-7850.
［19］Fu Z,Li D,Jiang W,et al.Association of BTLA gene polymorphisms with the risk of malignant breast cancer in Chinese women of Heilongjiang Province［J］.Breast Cancer Res Treat,2010,120:195-202.
［20］Gao X,Zhu Y,Li G,et al.TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression［J］.PloS One,2012，7(2):e30676．
［21］Xiao T,Zhang L,Chen L,et al.Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma［J］.Tumour Biol,2014，35(8):7951 -7956．
［22］Yang ZZ,Grote DM,Ziesmer SC,et al.IL-12 upregulates TIM-3cell non-Hodgkin lymphoma［J］.J Clin Invest,2012，122(4):1271-1282．
［23］Li H，Wu K，Tao K，et al.Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma［J］.Hepatology,2012,56(4):1342-1351.
［24］Fu-Jun Li,Ying Zhang,Guang-Xin Jin.Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+Tcell in HCC patients［J］.Immunology Letters,2013,150(1-2):116-122.
［25］Demeure CE,Wolf ers J,Martin-Garcia N,et al.T lymphocytes infiltrating various tumour types express the MHC class Ⅱligand lymphocyte activation gene-3(LAG-3):Role of LAG-3/MHC classⅡinteract ions in cell-cell contacts［J］.Eur J Cancer,2001,37(13):1709-1718.
［26］Matsuzaki J,Gnjatic S,Mhawech-Fauceglia P.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer［J］.Proc Natl Acad Sci USA,2010,107(17):7875-7880.
［27］Leach DR,Krummel MF,Allison JP.Enhancement of antitumor immunity by CTLA-4 blockade［J］.Science,1996,271(5256):1734-1736.
［28］Grosso JF,Jure-Kunkel MN.CTLA-4 blockade in tumor models:an overview of preclinical and translational research［J］.Cancer Immun,2013,13:5.
［29］Hodi FS,O' Day SJ,McDermott DF,et al.Improved survival with ipilimumab in patients with metastatic melanoma［J］.N Engl J Med,2010,363(8):711-723.
［30］Robert C,Thomas L,Bondarenko I,et al.Ipilimumab plus dacarbazine for previously untreated metastatic melanoma［J］.N Engl J Med,2011,364(26):2517-2526.
［31］Sharma P,Allison JP.The future of immune checkpoint therapy［J］.Science,2015,348(6230):56-61.
［32］Hamid O,Robert C,Daud A,et al.Safety and tumor responses with lambrolizumab(anti-PD-1) in melanoma［J］.N Engl J Med,2013,369(2):134-144.
［33］Robert C,Long GV,Brady B,et al.Nivolumab in previously untreated melanoma without BRAF mutation［J］.N Engl J Med,2015,372(4):320-330.
［34］Gettinger SN,Horn L,Gandhi L,et al.Overall survival and long-term safety of nivolumab(anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer［J］.J Clin Oncol,2015,33(18):2004-2012.
［35］Brahmer JR,Tykodi SS,Chow LQ,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer［J］.N Engl J Med,2012,366(26):2455-2465.
［36］Powles T,Eder JP,Fine GD,et al.MPDL3280A(anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer［J］.Nature,2014,515(7528):558-562.
［37］Herbst RS,Soria JC,Kowanetz M,et al.Predictive correlates of response to the anti-PD-L1 antibody MPDL 3280A in cancer patients［J］.Nature,2014,515:563-567.
［38］Ibrahim R,Stewart R,Shalabi A.PD-L1 blockade for cancer treatment:MEDI4736［J］.Semin Oncol,2015,42(3):474-483.
［39］Ott PA,Elez E,Hiret S,et al.Pembrolizumab in patients with extensive-stage samll-cell lung cancer:Results from the phase Ib KEYNOTE-028 study［J］.J Clin Oncol,2017,16:JCO2017725069.
［40］Chester C,Ambulkar S,Kohrt HE.4-1BB agonism:Adding the accelerator to cancer immunotherapy［J］.Cancer Immunology,Immunotherapy,2016,10:1243-1248．
［41］Chen DS,Mellman I.Elements of cancer immunity and the cancer-immune set point［J］.Nature,2017,541(7637):321-330.
［42］Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma［J］.N Engl J Med,2015,373(1):23-34.
［43］Crittenden M,Kohrt H,Levy R,et al.Current clinical trials testingcombinations of immunotherapy and radiation［J］.Semin Radiat Oncol,2015,25(1):54-64.